Revenues, Recognition and Allowances (Tables)

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenues

Net revenues for the three and nine months ended September 30, 2020 and 2019 are as follows:

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Company product sales	$	13,933	$	18,228	$	34,097	$	48,591
Contract manufacturing sales	306		167		813		1,097
Research and development services and other income	100		71		$	462	$	241
Revenue, net	$	14,339	$	18,466	$	35,372	$	49,929

Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations and is presented below according to product type:

	Three months ended September 30,				Nine months ended September 30,
Company Product Sales	2020		2019		2020		2019
Topical	$	11,982	$	13,271	$	26,138	$	35,240
Injectables	1,951		4,957		7,959		13,351
Total	$	13,933	$	18,228	$	34,097	$	48,591

Schedule of Accounts, Notes, Loans and Financing Receivable

The Company's adjustments for the deductions to gross product sales are as follows:

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Gross product sales	$	44,264	$	41,814	$	104,147	$	108,550
Deduction to gross product sales:
Chargebacks and billbacks	24,585		14,573		54,091		37,285
Wholesaler fees for service	1,445		2,355		4,191		6,303
Sales discounts and other allowances	4,302		6,658		11,769		16,371
Total reduction to gross product sales	$	30,332	$	23,586	$	70,051	$	59,959
Company product sales, net	$	13,933	$	18,228	$	34,097	$	48,591